As of November 6, 2026, Skye Bioscience, Inc. is a publicly traded company (Nasdaq: SKYE). The largest holder reporting an active stake on Schedule 13D is 5AM Partners VII, LLC, at 26.1%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Tang Capital Management, LLC (6%) (Schedule 13D/A, September 24, 2026).
Is this your company?
About to sign with, pay or invest in Skye Bioscience, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Skye Bioscience, Inc. a real, registered company?
- Skye Bioscience, Inc. files with the SEC under CIK 1516551 (its SEC filings).
- Its shares are listed under the ticker SKYE on Nasdaq (SEC company record).
- Incorporated in Nevada; business address in San Diego, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Skye Bioscience, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is John P. Sharp, Chief Financial Officer (Form 8-K filed 2026-09-11). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Tang Capital Management, LLC (filed 2026-10-14).
Who are Skye Bioscience, Inc.'s owners and officers?
Skye Bioscience, Inc.: incorporated in Nevada; business address in San Diego, California; industry Pharmaceutical Preparations (Schedule 13G, 2026-10-14).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2024-03-27)
- : Executive Officer (Form D, 2024-03-27)
- : Director (Form D, 2024-03-27)
- : Director (Form D, 2024-03-27)
- : Director (Form D, 2024-03-27)
- : Director (Form D, 2024-03-27)
- : Director (Form D, 2024-03-27)
- : Director (Form D, 2024-03-27)
- : Director (Form D, 2024-03-27)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-10-14 | Tang Capital Management, LLC | 6% |
| Schedule 13D/A, 2026-09-24 | 5am Partners Vii, LLC | 26.1% |
| Schedule 13D/A, 2026-08-18 | 5am Partners Vii, LLC | 30.2% |
| Schedule 13D/A, 2025-12-16 | 5am Partners Vii, LLC | 34% |
| Schedule 13G/A, 2025-08-14 | Schonfeld Strategic Advisors LLC | 3.6% |
Questions about who owns Skye Bioscience, Inc.
Who owns Skye Bioscience, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Skye Bioscience, Inc.: 5am Partners Vii, LLC (26.1%, Schedule 13D/A, filed 2026-09-24) and Tang Capital Management, LLC (6%, Schedule 13G, filed 2026-10-14).
Who are the largest shareholders of Skye Bioscience, Inc.?
By the share each holder's latest filing reports, the largest holders of Skye Bioscience, Inc. on this page are 5am Partners Vii, LLC (26.1%) and Tang Capital Management, LLC (6%).
When did 5am Partners Vii, LLC buy into Skye Bioscience, Inc.?
The filings give report dates, not purchase dates. The earliest filing from 5am Partners Vii, LLC on this page is the Schedule 13D/A, filed 2025-12-16, reporting 34%; its latest, Schedule 13D/A filed 2026-09-24, reports 26.1%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Skye Bioscience, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Skye Bioscience, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Skye Bioscience, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-09-11 | John P. Sharp | Chief Financial Officer | departed | |
| Form 8-K, 2026-09-11 | Punit Dhillon | President and Chief Executive Officer | appointed | 2026-09-08 |
| Form 8-K, 2026-04-03 | John P. Sharp | Chief Financial Officer | appointed |
Which insiders own Skye Bioscience, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and a director: 1,429,166 shares (4.0% of shares outstanding), 1,419,823 held directly and 9,343 indirectly (Form 4, 2026-08-07).
- 5AM Partners II, LLC, a 10% owner: 981,269 shares (2.8% of shares outstanding), held indirectly through By 5AM Co-Investors II, L.P. and 2 others, on a joint filing (Form 4, 2026-09-24).
- 5AM Ventures VII, L.P., a 10% owner: 981,269 shares (2.8% of shares outstanding), held indirectly through By 5AM Co-Investors II, L.P. and 2 others, on a joint filing (Form 4, 2026-09-24).
- , a 10% owner: 981,269 shares (2.8% of shares outstanding), held indirectly through By 5AM Co-Investors II, L.P. and 2 others, on a joint filing (Form 4, 2026-09-24).
- , a 10% owner: 981,269 shares (2.8% of shares outstanding), held indirectly through By 5AM Co-Investors II, L.P. and 2 others, on a joint filing (Form 4, 2026-09-24).
Shares outstanding: 35,421,413 as of 2026-08-10, from the company's latest SEC cover page.
How much has Skye Bioscience, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2024-03-27 | $40M | $40M |
| Form D, 2024-02-12 | $49.99M | $49.99M |
| Form D, 2023-08-29 | $62.25M | $62.25M |
Keep reading
More on Skye Bioscience, Inc. and the records around it.
Skye Bioscience, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Leadership changes Sep 2026
Companies that share a holder
- 5AM Partners VII, LLC also filed stake reports on 1 other company: Surrozen, Inc. (Aug 2026)
- Schonfeld Strategic Advisors LLC also filed stake reports on 5 other companies: Inhibrx Biosciences, Inc. (Aug 2026), Cardinal Infrastructure Group Inc. (May 2026), Jiuzi Holdings, Inc. (Feb 2026)
- TANG CAPITAL MANAGEMENT, LLC also filed stake reports on 33 other companies: EyePoint, Inc. (Oct 2026), Nano Dimension Ltd. (Aug 2026), Capricor Therapeutics, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/skye-bioscience